Use fundamental data analysis to confirm all available indicators of VanEck Vectors Biotech to find out if markets are presently mispricing the entity. We found eleven available drivers for VanEck Vectors Biotech ETF which can be compared to its competition. Please use VanEck Vectors One Year Return and Net Asset to make a decision on weather VanEck Vectors Biotech is priced fairly. Use VanEck Vectors to enhance returns of your portfolios. The etf experiences normal upward fluctuation. Check odds of VanEck Vectors to be traded at $124.48 in 30 days
VanEck Vectors Biotech ETF is rated below average in one year return as compared to similar ETFs. It is fourth largest ETF in five year return as compared to similar ETFs .
VanEck Vectors Biotech Systematic Risk
The output start index for this execution was twelve with a total number of output elements of twenty-seven. The Beta measures systematic risk based on how returns on VanEck Vectors Biotech correlated with the market. If Beta is less than 0 VanEck Vectors generally moves in the opposite direction as compared to the market. If VanEck Vectors Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one VanEck Vectors Biotech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of VanEck Vectors is generally in the same direction as the market. If Beta > 1 VanEck Vectors moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
VanEck Vectors Financial Distress Probability
Chance of Financial Distress
VanEck Vectors Biotech ETF has less than 26 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
Check also Trending Equities. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.